Glycominds, which develops a unique technology and provides via it CLIA certified clinical laboratory groundbreaking services for early detection and management of Multiple Sclerosis (MS), reported that it has received approval from the Japanese Patent Office for the registration of its application for a patent for its main process for early diagnosis and management of MS.
The approval of this Patent further strengthens the intellectual property of Glycominds and is an expansion of the extensive patent protection held by the company, which has more than 100 issued and registered patents. Glycominds now intends to examine possible entry into the Japanese market, which is considered the second largest market in the medical field.
Glycominds’ CLIA laboratory is processing the company's unique gMS blood tests, that dramatically shorten the time it takes to diagnose MS, and predict the course of progression of the disease. This technology allows the neurologist better treatment decision. Currently there are no competing blood tests for MS. The Company estimates the market potential for MS tests at about 1 billion dollars.
Glycominds recently reported the successful results of a clinical study of its prognostic test, the gMSPro CDMS. This test predicts events of clinical relapses in patients suspected with Multiple Sclerosis. The clinical study was held at the centre for Multiple Sclerosis of Catalonia, at the University Hospital Vall d'Hebron in Barcelona Spain, with a leading research group, led by Professor Xavier Montalban and Dr Mar Tintoré.
The gMSPro CDMS is the third test being developed by the Company. The two other tests: the gMSDx for early diagnosis of MS, and the gMSPro EDSS to predict the likelihood for rapid progression and accumulation of disabilities.
Dr Avinoam Dukler, CEO and president of Glycominds, said: "I am pleased that we have received the patent approval in Japan, which is an additional evidence of the technological innovation and the unique knowledge that we have developed at Glycominds. This approval is important and also supports the continued development of additional markets in the future for the company".
Glycominds, a molecular diagnostics company, develops and commercializes autoimmune and chronic inflammatory disease management tools and services with a distinctive focus on the Multiple Sclerosis market.